Therapy Areas: Oncology
Onward Therapeutics closes Series B financing
18 November 2026 -

Clinical-stage oncology company Onward Therapeutics Inc announced on Tuesday that it has closed its Series B financing of NTD900m (approximately USD28m).

The round was raised in two closings, the second of which took place in October 2026. It is the company's first capital increase in Taiwan since it completed its share exchange and moved its global headquarters from Switzerland to Taiwan in October 2025. Before the share exchange, the company had raised a total of CHF75.5m (approximately USD90m) in its previous rounds. Proceeds from the Series B will fund the company's clinical programmes, the manufacturing of clinical supplies, and early-stage R&D.

Existing individual and institutional shareholders, including CDIB Capital Healthcare Ventures and Hong Kong Chlitina International, continued to support the company in this round. New institutional investors include Beiley Biofund, Everbright Biofund, Test Rite International Co Ltd, Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture, and Top Taiwan Venture Capital. A number of individual investors also joined the round.

Onward Therapeutics' portfolio includes two clinical-stage programmes (an innovative bispecific antibody and an allogeneic cell therapy) and two early-stage drug discovery programmes.

Onward Therapeutics has signed a listing advisory agreement with a securities firm and begun preparing to register on the Taipei Exchange's Emerging Stock Board by the end of 2027. In addition, the company says that it plans to expand its team and start clinical trials in Taiwan, further strengthening its local R&D presence.

Login
Username:

Password: